{"id":"NCT00476242","sponsor":"New York State Psychiatric Institute","briefTitle":"Memantine as a Supplement to Naltrexone in Treating Heroin Dependence","officialTitle":"Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-06","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2007-05-21","resultsPosted":"2014-07-04","lastUpdate":"2018-07-17"},"enrollment":82,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Dependence","Heroin Dependence"],"interventions":[{"type":"DRUG","name":"Vivitrol","otherNames":["intramuscular injection of Vivitrol 380 mg"]},{"type":"DRUG","name":"memantine","otherNames":[]}],"arms":[{"label":"Memantine and Vivitrol","type":"EXPERIMENTAL"},{"label":"Placebo and Vivitrol","type":"PLACEBO_COMPARATOR"}],"summary":"Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to one of two conditions (1) Naltrexone + Placebo; (2) Naltrexone + Memantine 20 mg bid. Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per month (the total of three injections) while memantine or placebo will be taken daily. In addition, patients will receive twice weekly psychosocial intervention that will include motivational interviewing and cognitive-behavioral relapse prevention. The outpatient treatment will also consist of 3 weekly visits to the clinic in which patients will receive counseling to help maintain abstinence and improve compliance with study medication.","primaryOutcome":{"measure":"Opiate Use Measured by Urine Toxicology Results","timeFrame":"3x/week during 12 weeks of the trial or study participation","effectByArm":[{"arm":"Memantine and Vivitrol","deltaMin":9,"sd":null},{"arm":"Placebo and Vivitrol","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21715107"],"seeAlso":["http://www.stars.columbia.edu"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":28},"commonTop":["Insomnia","Mood changes","Fatigue/drowsiness","Increased/decreased appetite","GI Distress"]}}